News - Inimmune

Inimmune to present an Update on Clinical Stage Vaccine Adjuvant and Immunotherapy Programs at the World Vaccine Congress in Washington DC on April 1st

April 1, 2024

Medinvest Oncology Investor Conference

Inimmune to Present on Our Novel Cancer Immunotherapy INI-4001

December 6, 2023

World Vaccine Congress (West Coast)

Inimmune to Provide an Update on Our Vaccine and Adjuvant Programs

November 27, 2023

Latest News

Inimmune Announces Successful Phase 1 Clinical Results For Disease Modifying Allergy Treatment, INI-2004

Inimmune Announces Successful Phase 1 Clinical Results For Disease Modifying Allergy Treatment, INI-2004

Inimmune Announces First Cancer Patient Dosed in Phase 1 Clinical Study Using the Immunotherapeutic INI-4001, a Novel TLR7/8 Agonist

SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems

Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy

Inimmune to present on their Novel Cancer Immunotherapy INI-4001 at the Medinvest Oncology Conference on December 6th, 2023

Dr. Jay Evans, Inimmune’s Chief Scientific and Strategy Officer, will provide an update on our innovative vaccine and adjuvant programs on Wednesday, December 29, 2023 at the World Vaccine Congress (West Coast) in Santa Clara, CA

Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization

Inimmune announces collaboration with UChicago’s Pritzker School of Molecular Engineering (PME) professor Aaron Esser-Kahn to develop novel vaccine adjuvants

Biotech Company Announces $22 Million Investment Led by Mike Goguen’s Firm

For Missoula’s Inimmune, a $22 M Series A Round with Two Bear Capital is the latest record set

UM Receives Largest Single Research Award in its History

Inimmune Announces First Cancer Patient Dosed in Phase 1 Clinical Study Using the Immunotherapeutic INI-4001, a Novel TLR7/8 Agonist

SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems

Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy

Inimmune to present on their Novel Cancer Immunotherapy INI-4001 at the Medinvest Oncology Conference on December 6th, 2023

Dr. Jay Evans, Inimmune’s Chief Scientific and Strategy Officer, will provide an update on our innovative vaccine and adjuvant programs on Wednesday, December 29, 2023 at the World Vaccine Congress (West Coast) in Santa Clara, CA

Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization

Inimmune announces collaboration with UChicago’s Pritzker School of Molecular Engineering (PME) professor Aaron Esser-Kahn to develop novel vaccine adjuvants

Biotech Company Announces $22 Million Investment Led by Mike Goguen’s Firm

For Missoula’s Inimmune, a $22 M Series A Round with Two Bear Capital is the latest record set

UM Receives Largest Single Research Award in its History

Company

Quick Links

Legal

Contact